Diligence memo · auto-generated · as of July 2, 2026
March Therapeutics, Inc.
March Therapeutics, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
March Therapeutics, Inc. operates in Pharma, based in CAMBRIDGE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
March Therapeutics, Inc. has raised $23M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2022-09-12.
Most recent recorded round closed around 2022-09-12.
Valuation (modeled)modeled
Provath models March Therapeutics, Inc. at approximately $290M (range $43M–$732M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.37× the median modeled value of Series B Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (137% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 29 months.
Last raise 3.8 yr ago; this sector typically re-raises about every 16 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 7.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 78% of Pharma peers (310 compared).
Modeled value ranks above 80% of those peers.
Closest niche peers: Switch Therapeutics Inc., Affect Therapeutics, Inc., SPR Therapeutics, Inc., Multiply Labs, Inc., Notch Therapeutics, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.